Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus report

INTRODUCTION: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IB...

ver descrição completa

Detalhes bibliográficos
Autores: Rey, Enrique, Mearin, Fermín, Alcedo, Javier, Ciriza, Constanza, Delgado Aros, Silvia, Freitas, Teresa, Mascarenhas, Miguel, Mínguez, Miguel, Santos, Javier, Serra, Jordi
Formato: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2017
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/33182
Acesso em linha:http://hdl.handle.net/10230/33182
http://dx.doi.org/10.1007/s12325-016-0473-8
Access Level:acceso abierto
Palavra-chave:Gastroenterologia
Intestins -- Malalties
Abdominal pain
Constipation-predominant irritable bowel syndrome
Gastroenterology
Patient management
id ES_3d96b2ce04549593d9c9e0a038fdab2c
oai_identifier_str oai:recercat.cat:10230/33182
network_acronym_str ES
network_name_str España
repository_id_str
spelling Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus reportRey, EnriqueMearin, FermínAlcedo, JavierCiriza, ConstanzaDelgado Aros, SilviaFreitas, TeresaMascarenhas, MiguelMínguez, MiguelSantos, JavierSerra, JordiGastroenterologiaIntestins -- MalaltiesAbdominal painConstipation-predominant irritable bowel syndromeGastroenterologyPatient managementINTRODUCTION: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults. This review aims to facilitate and optimize clinical practices, establishing common guidelines to monitor patients with IBS-C that are treated with linaclotide. METHODS: A group of experts in functional digestive disorders was convened to review the efficacy and safety of linaclotide and to develop an updated consensus report for the treatment of patients with IBS-C. A search was performed for English, French and Spanish language articles in PubMed. On the basis of the articles identified, an initial document was drafted addressing different issues frequently raised by general practitioners and GI specialists that are related to the prescription, efficacy and safety of linaclotide. This document was then reviewed and modified by the expert panel until a final text was agreed upon and validated. RESULTS: Based on the evidence, the panel addressed the following recommendations: (1) Linaclotide is indicated for the treatment of moderate to severe IBS-C in adults; (2) it is recommended that patients take linaclotide continuously and not sporadically; (3) patients should be warned about the risk of diarrhea and given choices concerning how to deal with this possible side effect; (4) the absence of tachyphylaxis or potential risks implies that linaclotide treatment can be maintained for long periods of time. CONCLUSIONS: This document seeks to lay down a set of recommendations and to identify key issues that may be useful for the clinical management of IBS-C patients treated with linaclotide.Springer20172017info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/33182http://dx.doi.org/10.1007/s12325-016-0473-8reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésAdvances in Therapy. 2017 Mar;34(3):587-98© Springer The final publication is available at Springer via http://dx.doi.org/10.1007/s12325-016-0473-8.info:eu-repo/semantics/openAccessoai:recercat.cat:10230/331822026-05-29T05:05:01Z
dc.title.none.fl_str_mv Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus report
title Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus report
spellingShingle Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus report
Rey, Enrique
Gastroenterologia
Intestins -- Malalties
Abdominal pain
Constipation-predominant irritable bowel syndrome
Gastroenterology
Patient management
title_short Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus report
title_full Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus report
title_fullStr Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus report
title_full_unstemmed Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus report
title_sort Optimizing the use of linaclotide in patients with constipation-predominant irritable Bowel syndrome: an expert consensus report
dc.creator.none.fl_str_mv Rey, Enrique
Mearin, Fermín
Alcedo, Javier
Ciriza, Constanza
Delgado Aros, Silvia
Freitas, Teresa
Mascarenhas, Miguel
Mínguez, Miguel
Santos, Javier
Serra, Jordi
author Rey, Enrique
author_facet Rey, Enrique
Mearin, Fermín
Alcedo, Javier
Ciriza, Constanza
Delgado Aros, Silvia
Freitas, Teresa
Mascarenhas, Miguel
Mínguez, Miguel
Santos, Javier
Serra, Jordi
author_role author
author2 Mearin, Fermín
Alcedo, Javier
Ciriza, Constanza
Delgado Aros, Silvia
Freitas, Teresa
Mascarenhas, Miguel
Mínguez, Miguel
Santos, Javier
Serra, Jordi
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Gastroenterologia
Intestins -- Malalties
Abdominal pain
Constipation-predominant irritable bowel syndrome
Gastroenterology
Patient management
topic Gastroenterologia
Intestins -- Malalties
Abdominal pain
Constipation-predominant irritable bowel syndrome
Gastroenterology
Patient management
description INTRODUCTION: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults. This review aims to facilitate and optimize clinical practices, establishing common guidelines to monitor patients with IBS-C that are treated with linaclotide. METHODS: A group of experts in functional digestive disorders was convened to review the efficacy and safety of linaclotide and to develop an updated consensus report for the treatment of patients with IBS-C. A search was performed for English, French and Spanish language articles in PubMed. On the basis of the articles identified, an initial document was drafted addressing different issues frequently raised by general practitioners and GI specialists that are related to the prescription, efficacy and safety of linaclotide. This document was then reviewed and modified by the expert panel until a final text was agreed upon and validated. RESULTS: Based on the evidence, the panel addressed the following recommendations: (1) Linaclotide is indicated for the treatment of moderate to severe IBS-C in adults; (2) it is recommended that patients take linaclotide continuously and not sporadically; (3) patients should be warned about the risk of diarrhea and given choices concerning how to deal with this possible side effect; (4) the absence of tachyphylaxis or potential risks implies that linaclotide treatment can be maintained for long periods of time. CONCLUSIONS: This document seeks to lay down a set of recommendations and to identify key issues that may be useful for the clinical management of IBS-C patients treated with linaclotide.
publishDate 2017
dc.date.none.fl_str_mv 2017
2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/33182
http://dx.doi.org/10.1007/s12325-016-0473-8
url http://hdl.handle.net/10230/33182
http://dx.doi.org/10.1007/s12325-016-0473-8
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Advances in Therapy. 2017 Mar;34(3):587-98
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406456737955840
score 15,812455

Registos relacionados